New vaccine could save thousands of lives

February 29, 2016

Work led by University of Exeter experts could help to protect thousands of people from an often fatal disease found in most tropical regions.

Academics have created a vaccine which has the potential to protect humans from the infection melioidosis, also called Whitmore's disease.

The vaccine is the result of two decades of research, and is the most protective tested to date.

Melioidosis is caused by the bacterium Burkholderia pseudomallei. It is thought to be spread in soil and dust, but experts do not yet know why it only affects people and animals in . Occasionally people from the UK have contracted melioidosis while on holiday abroad.

There is an urgent need for an effective vaccine. In North-East Thailand melioidosis is the third most common cause of death from infectious diseases, exceeded only by HIV and tuberculosis. In Darwin, Northern Australia, melioidosis is the most common cause of fatal community-acquired septicemic pneumonia.

Melioidosis typically causes pneumonia and sepsis, and because these symptoms are similar to many other diseases it is often misdiagnosed. This means rates of people affected could be much higher than officially recorded.

The condition is hard to treat as B. pseudomallei is resistant to many antibiotics. Antibiotic courses lasting several months are usually required and patients often relapse.

Potential vaccines have been tested before, but none provided high level protection. Other vaccines against the disease tested on animals have given protection against the acute form of the disease but have failed to provide long-term control of persistent, chronic melioidosis.

Advances in technology mean experts at the University of Exeter have now been able to produce a vaccine which could help give humans protection against the disease. Preliminary studies have been carried out on mice, and it is hoped clinical trials on humans will take place in the future.

The vaccine is made up of a combination of different proteins, some of which help produce antibodies which boosts the immune system. However, unlike other melioidosis vaccines that have been tested previously, some of the proteins in the new induce immune responses to provide enhanced protection against chronic infection.

Professor Richard Titball, Professor of Molecular Microbiology, said: "Because of new technology we have been able to look at the genetic makeup of the bacterium and start to understand how the bacteria adapt to conditions during chronic infection.

"We now want to carry out further work to determine whether one or more of the proteins are responsible for this enhanced protection, and to test additional proteins to see if they can be protective antigens."

Academics from the University of Milan, the Defence Science and Technology Laboratory and the London School of Hygiene and Tropical Medicine were involved in the study, which was funded by the Fondazione CARIPLO, one of the world's main philanthropic organizations.

Immunisation with proteins expressed during chronic murine melioidosis provides enhanced protection against disease is published in the journal Vaccine.

Explore further: Deadly bacteria more prevalent than previously thought: study

Related Stories

Recommended for you

Zika virus infection alters human and viral RNA

October 20, 2016

Researchers at University of California San Diego School of Medicine have discovered that Zika virus infection leads to modifications of both viral and human genetic material. These modifications—chemical tags known as ...

Food-poisoning bacteria may be behind Crohn's disease

October 19, 2016

People who retain a particular bacterium in their gut after a bout of food poisoning may be at an increased risk of developing Crohn's disease later in life, according to a new study led by researchers at McMaster University.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.